Importance of angioedema-free days in patients with chronic idiopathic or spontaneous urticaria

We read with interest Dr Johnson's editorial1 that accompanied our analysis of data from 3 pivotal trials of omalizumab in chronic idiopathic/spontaneous urticaria (CIU/CSU).2 Dr Johnson suggested that, albeit statistically significant, the improvements in angioedema-free days might not be of clinical significance.

http://ift.tt/2oGgrpM